Search alternatives:
values decrease » values increased (Expand Search), largest decrease (Expand Search)
costs increased » cases increased (Expand Search), content increased (Expand Search), confers increased (Expand Search)
c largest » _ largest (Expand Search), c large (Expand Search)
i values » _ values (Expand Search)
ah costs » _ costs (Expand Search), a cost (Expand Search), a costa (Expand Search)
a large » _ large (Expand Search)
Showing 81 - 100 results of 31,896 for search '(( ((c largest) OR (a large)) decrease ) OR ((( i values decrease ) OR ( ah costs increased ))))', query time: 2.07s Refine Results
  1. 81
    Benchmarking DFT Accuracy in Predicting O 1s Binding Energies on Metals

    Benchmarking DFT Accuracy in Predicting O 1s Binding Energies on Metals by Elizabeth E. Happel (22391811)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 82
    The computed weighted sum of type I (dark gray) and type II (light gray) errors (

    The computed weighted sum of type I (dark gray) and type II (light gray) errors ( by Farrokh Habibzadeh (12256529)

    Published 2025
    Save to List
    Saved in:
  3. 83
    The computed weighted sum of type I (dark gray) and type II (light gray) errors (

    The computed weighted sum of type I (dark gray) and type II (light gray) errors ( by Farrokh Habibzadeh (12256529)

    Published 2025
    Save to List
    Saved in:
  4. 84
    The computed weighted sum of type I (dark gray) and type II (light gray) errors (

    The computed weighted sum of type I (dark gray) and type II (light gray) errors ( by Farrokh Habibzadeh (12256529)

    Published 2025
    Save to List
    Saved in:
  5. 85
    Polylactic Acid/Polybutylene Adipate Terephthalate-Carbon Nanotube Nanobiocomposites with a Segregated Toughening Morphology Yielding Large Ductility for Biocompatible Materials

    Polylactic Acid/Polybutylene Adipate Terephthalate-Carbon Nanotube Nanobiocomposites with a Segregated Toughening Morphology Yielding Large Ductility for Biocompatible Materials by Utsab Ayan (18552401)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 86
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  7. 87
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 88
    Linear regressions of consumer stable carbon and nitrogen isotope values and collection date.

    Linear regressions of consumer stable carbon and nitrogen isotope values and collection date. by Nathan D. McTigue (10706460)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 89
    Mathematical treatments applied to data to correct stable isotope values for lipid content.

    Mathematical treatments applied to data to correct stable isotope values for lipid content. by Nathan D. McTigue (10706460)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 90
    The number of expected vaccinations decreases with the expected vaccination time, whereas the peak of infections increases.

    The number of expected vaccinations decreases with the expected vaccination time, whereas the peak of infections increases. by Simon K. Schnyder (16632244)

    Published 2023
    Save to List
    Saved in:
  11. 91
    MC depletion decreases aneurysmal growth after dissections in ApoE-RMB mice.

    MC depletion decreases aneurysmal growth after dissections in ApoE-RMB mice. by Alexia Loste (17592915)

    Published 2023
    Save to List
    Saved in:
  12. 92
    Costs and Benefits of Popular <i>P</i>‑Value Correction Methods in Three Models of Quantitative Omic Experiments

    Costs and Benefits of Popular <i>P</i>‑Value Correction Methods in Three Models of Quantitative Omic Experiments by Steven R. Shuken (14500192)

    Published 2023
    “…The tremendous false discovery rate (FDR) benefit of correction was confirmed in a range of different contexts. No correction method can guarantee a low FDP in a single experiment, but the probability of a high FDP is small when a high number and proportion of corrected <i>p</i>-values are significant. …”
    Save to List
    Saved in:
  13. 93
    Proportion of genotype calls with both alleles correct (2), one allele incorrect (1) and two alleles incorrect (0) at different sequencing coverages.

    Proportion of genotype calls with both alleles correct (2), one allele incorrect (1) and two alleles incorrect (0) at different sequencing coverages. by Harrison J. Lamb (11722247)

    Published 2021
    Save to List
    Saved in:
  14. 94
    Survival probability of cercariae in 0.38 ppt, 1.9 ppt, 3.8 ppt, and 5.7 ppt salinity treatments over a 24-hour period.

    Survival probability of cercariae in 0.38 ppt, 1.9 ppt, 3.8 ppt, and 5.7 ppt salinity treatments over a 24-hour period. by Ao Yu (1348512)

    Published 2022
    Save to List
    Saved in:
  15. 95
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 96
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 97
    Species occurrence along the NO₃¯ gradient (sorted by decreasing 25th percentile values).

    Species occurrence along the NO₃¯ gradient (sorted by decreasing 25th percentile values). by Willem Kaijser (12872371)

    Published 2022
    Save to List
    Saved in:
  18. 98
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 99
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  20. 100
    The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription.

    The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. by Peiqi Yin (6533747)

    Published 2025
    Save to List
    Saved in:

Search Tools: